Disorders of purines and pyrimidines

Handbook of Clinical Neurology

Volumn 120, Issue , 2014, Pages 827-838

  Kelley, Roger E ^a   Andersson, Hans C ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arts syndrome; Gout; Hepatocerebral syndrome; Lesch Nyhan syndrome; Orotic aciduria; Purine metabolism; Pyrimidine metabolism; Von Gierke disease

Indexed keywords

PURINE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; ARTS SYNDROME; GLYCOGEN STORAGE DISEASE TYPE 1; GOUT; HEPATIC ENCEPHALOPATHY; HUMAN; LESCH NYHAN SYNDROME; METABOLIC DISORDER; METABOLISM; NEUROLOGIC DISEASE; OROTIC ACIDURIA; PURINE METABOLISM; PYRIMIDINE METABOLISM;

ARTS SYNDROME; GOUT; HEPATOCEREBRAL SYNDROME; LESCH-NYHAN SYNDROME; OROTIC ACIDURIA; PURINE METABOLISM; PYRIMIDINE METABOLISM; VON GIERKE DISEASE;

HUMANS; METABOLIC DISEASES; NERVOUS SYSTEM DISEASES; PURINES; PYRIMIDINES;

EID: 84890810972     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4087-0.00055-3     Document Type: Chapter

References (69)

1. Assmann B., Gohlich-Ratmann G., Brautigam L., et al. Presumptive ureidopropionase deficiency as a new defect in pyrimidine catabolism found with in vitro H-NMR spectroscopy. J Inherit Metab Dis 1998, 21(Suppl. 2):1.
2. Bakkeren J.A.J.M., De Abreau R.A., Sengers R.C.A., et al. Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency. Clin Chim Acta 1984, 140:247-254.
3. Becker M.A., Losman M.J., Kim M. Mechanism of accelerated purine nucleotide synthesis in human fibroblasts with superactive phosphoribosylpyrophosphate synthetase. J Biol Chem 1987, 262:5596-5602.
4. Becker M.A., Losman M.J., Wilson J., et al. Superactivity of phosphoribosylpyrophosphate synthetase due to altered regulation by nucleotide inhibitors and inorganic phosphate. Biochim Biophys Acta 1988, 882:168-176.
5. Becker M.A., Puig J.G., Mateos F.A., et al. Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorial deafness. Am J Med 1988, 85:383-390.
6. Becker M.A., Smithy P.R., Taylor W., et al. The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest 1995, 96:2133-2141.
7. Berger R., Stoker-de Vries S.A., Wadman S.K., et al. Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. Clin Chim Acta 1984, 141:227-234.
8. Blau N., de Klerk K.J., Thony B., et al. Tetrahydrobiopterin loading test in xanthine dehydrogenase and molybdenum cofactor deficiencies. Biochem Mol Med 1996, 58:199-206.
9. Bzowska A., Kulikowska E., Shugar D. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Ther 2000, 88:349-425.
10. Calabrese G., Simmonds H.A., Cameron J.S., et al. Precocious familial gout with reduced fractional urate clearance and normal purine enzymes. Q J Med 1990, 75:441-450.
11. Camici M., Micheli V., Ipata P.L., et al. Pediatric neurological syndromes and inborn errors of purine metabolism. Neurochem Int 2010, 56:367-378.
12. Chalmers R.A., Watts R.W., Bitensky J., et al. Microscopic studies on crystals in skeletal muscle from two cases of xanthinuria. J Pathol 1969, 99:45-49.
13. Chou J.Y., Mansfield B.C. Gene therapy for type I glycogen storage diseases. Curr Gene Ther 2007, 7:79-88.
14. Chou J.Y., Matern D., Mansfield B.C., et al. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2002, 2:121-143.
15. Crifò C., Siems W., Soro S., et al. Inhibition of defective adenylsuccinate lyase by HNE: a neurological disease that may be affected by oxidative stress. Biofactors 2005, 24:131-136.
16. Dalal I., Grunebaum E., Cohen A., et al. Two novel mutations in a purine nucleoside phosphorylase (PNP)-deficient patient. Clin Genet 2001, 59:430-437.
17. De Brouwer A.P.M., Williams K.L., Duley J.A., et al. Arts syndrome is caused by loss-of-function mutations in PRPS1. Am J Hum Genet 2007, 81:507-518.
18. De Volder A.G., Jaeken J., Van den Berghe G., et al. Regional brain glucose utilization in adenylosuccinase-deficient patients measured by positron emission tomography. Pediatr Res 1988, 24:238-242.
19. Endres W., Shin Y.S., Gunther R., et al. Report on a new patient with combined deficiencies of sulphite oxidase and xanthine dehydrogenase due to molybdenum cofactor deficiency. Eur J Pediatr 1988, 148:246-252.
20. Eriksson S., Wang L. Molecular mechanism of mitochondrial DNA depletion diseases caused by deficiencies in enzymes in purine and pyrimidine metabolism. Nucleosides Nucleotides Nucleic Acids 2008, 27:800-808.
21. Eriksson S., Munch-Petersen B., Johansson K., et al. Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 2002, 59:1327-1346.
22. Fishbein W.N., Armbrustmacher V.W., Griffin J.L. Myoadenylate deaminase deficiency: a new disease of muscle. Science 1978, 200:545-551.
23. Fox I.H., Kelley W.N. Human phosphoribosylpyrophosphate synthetase. Kinetic mechanism and end product inhibition. J Biol Chem 1972, 247:2126-2131.
24. Giblett E.R., Anderson J.E., Cohen F., et al. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 2:1067-1072.
25. Giblett E.R., Amman A.J., Wara D.W., et al. Nucleoside phosphorylase deficiency in a child with severely defective T cell immunity and normal B cell immunity. Lancet 1975, 1:1010-1013.
26. Hamajima N., Kouwaki M., Vreken P., et al. Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene. Am J Hum Genet 1998, 63:717-728.
27. Hirschhorn R. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediatr Res 1993, 33:35-41.
28. Hirschhorn R., Papageorgiou P.S., Kesarwala H.H. Amelioration of neurological abnormalities after enzyme replacement of adenosine deaminase deficieincy. N Engl J Med 1980, 303:377-380.
29. Huguley C., Bain J., Rivers R., et al. Refractory megaloblastic anaemia associated with excretion of orotic acid. Blood 1959, 14:615-618.
30. Ichida K., Amaya Y., Kamatani N., et al. Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J Clin Invest 1997, 99:2391-2399.
31. Janecke A.R., Mayatepek E., Utermann G. Molecular genetics of type 1 glycogen storage disease. Mol Genet Metab 2001, 73:117-125.
32. Jinnah H.A., Visser J.E., Harris J.C., et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006, 129:1201-1217.
33. Johansson M., Bajalic-Lagercrantz S., Lagercrantz J., et al. Localization of the human deoxyguanosine kinase gene (DGUOK) to chromosome 2p13. Genomics 1996, 38:450-451.
34. Johnson J. Prenatal diagnosis of molybdenum cofactor deficiency and isolated sulphite oxidase deficiency. Prenat Diagn 2003, 23:6-9.
35. Kelley W.N., Greene M.L., Rosenbloom F.M., et al. Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout. Ann Intern Med 1969, 70:155-206.
36. Kim H.-J., Sohn K.-M., Shy M.E., et al. Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic atrophy (CMTX5). Am J Hum Genet 2007, 81:552-558.
37. Krishnan E., Svendsen K., Neaton J.D., et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008, 168:1104-1110. MRFIT Research Group.
38. Labarthe F., Dobbelaere D., Devisma L., et al. Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. J Hepatol 2005, 43:333-341.
39. Laikind P.K., Seegmiller J.E., Gruber H.E. Detection of 5'-phosphoribosyl-4-(N-succinylcarboxamide)-5-aminoimidazole in urine by use of the Bratton-Marshall reaction: identification of patients deficient in adenylosuccinate lyase activity. Analyt Biochem 1986, 156:81-90.
40. Lesch M., Nyhan W.L. A familial disorder of uric acid metabolism and central nervous system function. Am J Med 1964, 36:561-567.
41. Mandel H., Szargel R., Labay V., et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001, 29:337-341.
42. Marie S., Heron P., Bitoun P., et al. AICA-ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. Am J Hum Genet 2004, 74:1276-1281.
43. Markert M.L. Molecular basis of adenosine deaminase deficiency. Immunodeficiency 1994, 5:141-145.
44. Meinsma R., Fernandez-Salguero P., Van Kuilenburg A., et al. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uraciluria. DNA Cell Biol 1995, 14:1-7.
45. Morisaki T., Gross M., Morisaki H., et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci 1992, 89:6457-6461.
46. Nguyen K.V., Naviaux R.K., Paik K.K., et al. Lesch-Nyhan syndrome: mRNA expression of HPRT in patients with enzyme proven deficiency of HPRT and normal HPRT coding region of the DNA. Mol Genet Metab 2012, 106:498-501.
47. Nofech-Mozes Y., Blaser S.I., Kobayashi J., et al. Neurologic abnormalities in patients with adenosine deaminase deficiency. Pediatr Neurol 2007, 37:218-221.
48. Nyhan W.L. Disorders of purine and pyrimidine metabolism. Mol Genet Metab 2005, 86:25-33.
49. Page T., Bakay B., Nissinen E., et al. Hypoxanthine guanine phosphoribosyl transferase variants: correlation of clinical phenotype with enzyme activity. J Inherit Metab Dis 1981, 4:203-207.
50. Page T., Yu A., Fontanesi J., et al. Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci U S A 1997, 94:11601-11606.
51. Pesi R., Micheli V., Jacomelli G., et al. Cystolic 5'-nucleotidase hyperactivity in erythrocytes of Lesch-Nyhan syndrome patients. Neuroreport 2000, 11:1827-1831.
52. Rogers M.H., Lwin R., Fairbanks L., et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr 2001, 139:44-50.
53. Salerno C., Iotti R., Lodi R., et al. Failure of muscle energy metabolism in a patient with adenylosuccinase deficiency An in vivo study by phosphorus NMR spectroscopy. Biochim Biophys Acta 1997, 1360:271-276.
54. Salerno C., D'Eufemia P., Finocchiaro R., et al. Effect of D-ribose on purine synthesis and neurological symptoms in a patient with adenylosuccinase deficiency. Biochim Biophys Acta 1999, 1453:135-140.
55. Salgueiro N., Veiga I., Fragoso M., et al. Mutations in exon 14 of dihydropyridimine dehydrogenase and 5'-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 2004, 6:102-107.
56. Salviati L., Sacconi S., Mancuso M., et al. Mitochondrial DNA depletion and dGK gene mutations. Ann Neurol 2002, 52:311-317.
57. Schlesinger N. Diagnosing and treating gout: a review to aid primary care physicians. Postgrad Med 2010, 122:157-161.
58. Sidi Y., Mitchell B.S. Z-nucleotide accumulation in erythrocytes from Lesch-Nyhan patients. J Clin Invest 1985, 76:2416-2419.
59. Smith L.J., Sullivan M., Huguley C. Pyrimidine metabolism in man IV The enzymatic defect of orotic aciduria. J Clin Invest 1961, 40:656-661.
60. Spiegel E.K., Colman R.F., Patterson D. Adenylosuccinate lyase deficiency. Mol Genet Metab 2006, 89:19-31.
61. Suchi M., Mizuno H., Kawai Y., et al. Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am J Hum Genet 1997, 60:525-539.
62. Sumi S., Suchi K., Kidouchi H., et al. Pyrimidine metabolism in hereditary orotic aciduria. J Inherit Metab Dis 1997, 20:104-105.
63. Trifilo M., Page T. NAPDD patients exhibit altered electrophoretic mobility of cytosolic 5'nucleotidase. Adv Exp Med Biol 2000, 486:87-90.
64. Turner J.J., Stacey J.M., Harding B., et al. UROMODULIN mutations cause familial juvenile hyperuricemic nephropathy. J Clin Endocrinol Metab 2003, 88:1398-1401.
65. Van Gennip A., Abeling N., Vreken P., et al. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis 1997, 20:203-208.
66. van Kuilenburg A.B.P., Meinsma R., Beke E., et al. B-ureipropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Hum Mol Genet 2004, 13:2793-2801.
67. Wada Y., Nishimura Y., Tanabu M., et al. Hypouricemic mentally retarded infant with a defect of 5-phosphoribosyl-1-pyrophosphate synthetase of erythrociytes. Tohoku J Exp Med 1974, 113:149-157.
68. Wadman S.K., Duran M., Beemer F.A., et al. Absence of hepatic molybdenum cofactor: an inborn error of metabolism leading to a combined deficiency of suphite oxidase and xanthine dehydrogenase. J Inherit Metab Dis 1983, 6(Suppl 1):78.
69. Wong D.F., Harris J.C., Naidu S., et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A 1996, 93:5539-5543.